Page last updated: 2024-09-03

gefitinib and Astrocytoma, Grade IV

gefitinib has been researched along with Astrocytoma, Grade IV in 67 studies

Research

Studies (67)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	25 (37.31)	29.6817
2010's	38 (56.72)	24.3611
2020's	4 (5.97)	2.80

Authors

Authors	Studies
Cheng, F; Dong, M; Guo, D; He, Y; Hu, J; Lei, T; Li, X; Mao, F; Tang, Q; Wan, F; Wang, B; Xiao, Q; Yu, X; Zhang, P; Zong, W	1
Blandin, AF; Choulier, L; Cruz Da Silva, E; Dedieu, S; Devy, J; Didier, P; Dontenwill, M; Etienne-Selloum, N; Glushonkov, O; Lehmann, M; Mercier, MC; Schneider, C	1
Day, EK; Lazzara, MJ; Purow, B; Zhong, Q	1
Hossienpour, M; Karami, A; Kiani, A; Mohammadi Noori, E; Najafi, K; Rahpyma, M	1
Breunig, JJ; Chan, SL; Chen, Y; Ching, J; Ding, LW; Doan, N; Dutra-Clarke, M; Hazawa, M; Jiang, YY; Koeffler, HP; Kovalik, JP; Lin, DC; Madan, V; Mayakonda, A; Müschen, M; Said, JW; Savinoff, SE; Tyner, JW; Watkins, A; Xu, L; Yang, H; Yong, WH	1
Burgio, F; Faia-Torres, AB; Fontana, AO; Marchi, F; Paganetti, P; Pieles, U; Piffaretti, D; Pinton, S; Reinert, M	1
Szabo, E; von Achenbach, C; Weller, M	1
Canoll, P; Foshay, K; Kleinschmidt-DeMasters, BK; Niswander, L; Parker, JJ; Waziri, A	1
Chen, G; Dang, YW; He, RQ; Luo, DZ; Xiong, DD; Xu, WQ	1
Han, S; He, QH; Li, P; Liu, KY; Liu, XJ; Liu, XX; Liu, YN; Ma, SH; Qin, JZ; Shen, L; Wu, WH; Wu, WT; Yin, F; Zhang, JM; Zhang, XY	1
Carrillo, V; Dubisz, E; Gulzar, H; Mahajan, SS; Morgan, D; Yelskaya, Z	1
Canoll, P; Dionne, KR; Foreman, NK; Klaassen, M; Kleinschmidt-Demasters, BK; Massarwa, R; Niswander, L; Parker, JJ; Waziri, A	1
Gallo, JM; Lv, H; Sharma, J	2
Baskaran, S; Forsberg Nilsson, K; Gerlee, P; Häggblad, M; Hansson, C; Karlsson-Lindahl, L; Kling, T; Lundgren, B; Martens, U; Monsefi, N; Nelander, S; Olsson, M; Schmidt, L; Uhrbom, L; Westermark, B	1
Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY	1
Homicsko, K; Hottinger, AF; Stupp, R	1
Buonato, JM; Furcht, CM; Lazzara, MJ; Mathew, LK; Muñoz Rojas, AR; Simon, MC; Skuli, N	1
Cavenee, WK; Furnari, FB; Gonias, SL; Hu, J; Muller, KA; VandenBerg, SR	1
Perek, N; Prevot, N; Puech, C	1
Cavenee, WK; Chen, CC; Furnari, FB; Gomez, GG; Gonias, SL; Hu, J; Mischel, PS; Pizzo, D; Taylor, T; Thorne, AH; VandenBerg, SR; Villa, GR; Wykosky, J	1
Hara, A; Iwama, T; Kunisada, T; Park, DM; Soeda, A; Yoshimura, S	1
Aljohani, H; Bahassi, el M; Koncar, RF; Lee, SH; Park, BS; Zarzour, A	1
Dikomey, E; Gal, A; Grob, TJ; Kriegs, M; Lamszus, K; Petersen, C; Rieckmann, T; Riedel, M; Rothkamm, K; Schulte, A; Struve, N	1
Amoresano, A; Camorani, S; Carpentieri, A; Cerchia, L; Chiariello, M; Colecchia, D; Crescenzi, E; Fedele, M	1
Clark, SW; Ma, Y; Mobley, BC; Sarkaria, JN; Tang, N; Thompson, RC; Wang, J	1
Brown, N; Clifton-Hadley, L; Dungey, F; Hopkins, K; Jeffries, S; Khan, I; Krell, D; McBain, C; Mulholland, P; Nash, S; Phillips, M; Sanghera, P; Saran, F; Smith, P; Wanek, K	1
Chen, Y; Mu, L; Tang, X; Wang, T; Yuan, Y; Zhao, Y	1
Andäng, M; Baskaran, S; Claesson-Welsh, L; Elfineh, L; Forsberg-Nilsson, K; Green, LC; Häggblad, M; Johansson, P; Krona, C; Lönnstedt, I; Lundgren, B; Martens, U; Matuszewski, D; Nelander, S; Padhan, N; Schmidt, L; Sintorn, IM; Uhrbom, L; Wee, S; Westermark, B	1
Bachoo, RM; Cho, SK; Hatanpaa, KJ; Humphries, CG; Kim, RS; Kittler, R; Klingler, S; Kollipara, RK; Maher, EA; Mashimo, T; Mickey, B; Nannepaga, S; Piccirillo, S; Raisanen, J; Regmi, N; Singh, DK; Sirasanagandla, S; Sun, Y; Vemireddy, V; Wang, S; Yang, XL; Zheng, H	1
Benveniste, EN; Dees, KJ; Gibson, SA; Hjelmeland, AB; McFarland, BC; Meares, GP; Nozell, SE; Rajbhandari, R; Rowse, AL	1
Ahmadinia, L; Alimoghaddam, K; Amanpour, S; Barghi, F; Dardaei, L; Dehpour, AR; Emami, AH; Eyvani, H; Ghaffari, SH; Ghavamzadeh, A; Ghazi-Khansari, M; Gortany, NK; Mirshahvaladi, S; Moghaddaskho, F; Momeny, M; Sabourinejad, Z; Tavangar, SM; Yousefi, H; Zarrinrad, G	1
Barrett, GM; Cemeus, C; Dimitroulakos, J; Lorimer, IA; Zhao, TT	1
Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP	1
Chen, C; Gaspar, LE; Kavanagh, BD; Kleinschmidt-De Masters, BK; McCammon, R; Schwer, AL; Stuhr, K	1
Abrey, LE; Kreisl, TN; Lassman, AB; Lis, E; Mischel, PS; Rosen, N; Scher, HI; Shaffer, D; Teruya-Feldstein, J	1
Gallo, JM; Wang, S; Zhou, Q	1
Ali-Osman, F; Cao, X; Keir, S; Lo, HW; Zhu, H	1
Ballman, KV; Behrens, RJ; Buckner, JC; Dakhill, SR; Flynn, PJ; Giannini, C; Jaeckle, KA; James, CD; Krauss, JC; Schaefer, PL; Scheithauer, BW; Uhm, JH; Wu, W	1
Bady, P; Delorenzi, M; Diserens, AC; Frei, K; Hamou, MF; Hegi, ME; Heppner, FL; Hofer, S; Kamoshima, Y; Koch, A; Kouwenhoven, MC; Lambiv, WL; Mariani, L; Matter, MS; Merlo, A; Yonekawa, Y	1
Baryawno, N; Ekström, TJ; Johnsen, JI; Larsson, C; Marino, AM; Sofiadis, A; Vukojević, V	1
Cavenee, WK; Furnari, F; Gonias, SL; Hu, J; Jo, M; VandenBerg, SR	1
Acquaviva, J; Boskovitz, A; Bronson, RT; Charest, A; Donovan, M; Housman, DE; Jun, HJ; Lessard, J; Pfannl, R; Raval, A; Ruiz, R; Whittaker, CA; Woolfenden, S; Zhu, H	1
Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA	1
Braoudaki, M; Hatziagapiou, K; Karpusas, M; Tzortzatou-Stathopoulou, F	1
Gallia, GL; Joshi, AD; Loilome, W; Riggins, GJ; Siu, IM; Tyler, B	1
Brachman, DG; Bredel, M; Chakravarti, A; Choucair, A; Christiansen, J; Curran, WJ; Dicker, AP; Dolled-Filhart, M; Gustavson, M; Lautenschlaeger, T; Mehta, M; Mischel, P; Molinaro, A; Robins, HI; Schultz, CJ; Wang, M	1
Ahmed Rasheed, BK; Bigner, DD; Dancey, JE; Dowell, JM; Friedman, AH; Friedman, HS; Herndon, JE; Kao, JC; McLendon, RE; Peery, T; Penne, KL; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Stenzel, TT; Tourt-Uhlig, SE; Van Duyn, LB; Vredenburgh, JJ; Wikstrand, CJ	1
Ambrad, AA; Carey, S; Falsey, R; Glanzberg, H; Kislin, K; Martinez, JD; Meuillet, EJ; Patel, J; Stea, B	1
Ochs, JS	1
Archer, GE; Bigner, DD; Friedman, AH; Friedman, HS; Hartzell, TL; Learn, CA; Rich, JN; Sampson, JH; Wikstrand, CJ	1
Aderka, D; Levitt, ML; Pfeffer, MR	1
Rasheed, BK; Rich, JN; Yan, H	1
Carpentier, AF	1
Barber, TD; Kinzler, KW; Velculescu, VE; Vogelstein, B	1
Carpentier, AF; Delattre, JY; Hoang-Xuan, K; Marie, Y; Omuro, AM; Sanson, M; Thillet, J	1
Raizer, JJ	1
Bigner, DD; Friedman, HS	1
Beroukhim, R; Cavenee, WK; Chute, DJ; Cloughesy, TF; Dia, EQ; Haas-Kogan, DA; Horvath, S; Huang, JH; Lee, JC; Liau, LM; Lu, KV; Mellinghoff, IK; Mischel, PS; Peck, TC; Prados, M; Rao, PN; Riggs, BL; Sawyers, CL; Sellers, WR; Stokoe, D; Vivanco, I; Wang, MY; Yoshimoto, K; Zhu, S	1
Abrey, LE; Gilbert, MR; Lassman, AB	1
Behnke-Mursch, J; Halatsch, ME; Schmidt, U; Unterberg, A; Wirtz, CR	1
Frei, K; Hofer, S; Rutz, HP	1
Pedersen, MW; Poulsen, HS	1
Frei, K; Hofer, S	1
Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK	1
Gallo, JM; Guo, P; Wang, S; Wang, X; Zhou, Q	1
Liau, LM; Salgaller, ML	1

Reviews

8 review(s) available for gefitinib and Astrocytoma, Grade IV

Article	Year
Standards of care and novel approaches in the management of glioblastoma multiforme. Chinese journal of cancer, 2014, Volume: 33, Issue:1 Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Cancer Vaccines; Electric Stimulation Therapy; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Immunotherapy; Quinazolines; Snake Venoms; Standard of Care; Vaccines, Subunit	2014
Genetics of glioblastoma: a window into its imaging and histopathologic variability. Radiographics : a review publication of the Radiological Society of North America, Inc, 2011, Volume: 31, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines	2011
Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. International journal of radiation oncology, biology, physics, 2004, Mar-01, Volume: 58, Issue:3 Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplasms; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents	2004
Neuro-oncology: the growing role of chemotherapy in glioma. The Lancet. Neurology, 2005, Volume: 4, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Resistance, Neoplasm; Gefitinib; Glioblastoma; Glioma; Humans; Meta-Analysis as Topic; Nitrosourea Compounds; Oligodendroglioma; Paraneoplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Temozolomide	2005
HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. Journal of neuro-oncology, 2005, Volume: 74, Issue:1 Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction	2005
Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer treatment reviews, 2006, Volume: 32, Issue:2 Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines	2006
[Mutations in the epidermal growth factor receptor: structure and biological function in human tumors]. Ugeskrift for laeger, 2006, Jun-12, Volume: 168, Issue:24 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Lung Neoplasms; Mutation; Neoplasms; Prognosis; Quinazolines; Receptor Protein-Tyrosine Kinases	2006
Current status of clinical trials for glioblastoma. Reviews on recent clinical trials, 2006, Volume: 1, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors	2006

Trials

8 trial(s) available for gefitinib and Astrocytoma, Grade IV

Article	Year
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma. PloS one, 2016, Volume: 11, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Placebos; Quality of Life; Quinazolines; Recurrence; Safety; Vascular Endothelial Growth Factor A	2016
Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas. International journal of radiation oncology, biology, physics, 2009, Apr-01, Volume: 73, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Radiosurgery; Tumor Burden; Young Adult	2009
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). Journal of neuro-oncology, 2009, Volume: 92, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; ErbB Receptors; Everolimus; Female; Gefitinib; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Sirolimus	2009
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. International journal of radiation oncology, biology, physics, 2011, Jun-01, Volume: 80, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Dexamethasone; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Enzyme Activators; ErbB Receptors; Female; Gefitinib; Gene Amplification; Genes, erbB-1; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Quinazolines; Young Adult	2011
Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial. Molecular cancer therapeutics, 2011, Volume: 10, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Young Adult	2011
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. International journal of radiation oncology, biology, physics, 2013, Apr-01, Volume: 85, Issue:5 Topics: Age Factors; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Maximum Tolerated Dose; Middle Aged; Quinazolines; Radiotherapy Dosage	2013
Phase II trial of gefitinib in recurrent glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1 Topics: Adult; Aged; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome	2004
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:6 Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Edema; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Gefitinib; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Quinazolines; Temozolomide	2008

Other Studies

51 other study(ies) available for gefitinib and Astrocytoma, Grade IV

Article	Year
Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling. Cancer gene therapy, 2020, Volume: 27, Issue:12 Topics: Animals; Axl Receptor Tyrosine Kinase; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Intercellular Signaling Peptides and Proteins; Male; Membrane Glycoproteins; Mice; Mice, Nude; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction; src-Family Kinases; Up-Regulation; Xenograft Model Antitumor Assays	2020
Gefitinib induces EGFR and α5β1 integrin co-endocytosis in glioblastoma cells. Cellular and molecular life sciences : CMLS, 2021, Volume: 78, Issue:6 Topics: Brain Neoplasms; Cell Line, Tumor; Cell Membrane; Cell Movement; Endocytosis; Endosomes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Integrin alpha5beta1; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering	2021
Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition. Cancer research, 2021, 04-15, Volume: 81, Issue:8 Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Data Science; Dimethyl Sulfoxide; DNA Repair; Drug Resistance, Neoplasm; Female; Gefitinib; Glioblastoma; Heterografts; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Least-Squares Analysis; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, SCID; Models, Biological; Neoplasm Transplantation; Phenotype; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Ribonucleoproteins, Small Nuclear; Signal Transduction; src Homology Domains; Sulfones; Temozolomide; Transcription Factor AP-1	2021
Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis. Nutrition and cancer, 2022, Volume: 74, Issue:4 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Glioblastoma; Glioma; Humans; Neovascularization, Pathologic; Temozolomide; Vascular Endothelial Growth Factor A	2022
BCL6 promotes glioma and serves as a therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 2017, 04-11, Volume: 114, Issue:15 Topics: Animals; Axl Receptor Tyrosine Kinase; Brain Neoplasms; Cell Line, Tumor; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; MAP Kinase Kinase Kinases; Mice, Mutant Strains; Molecular Targeted Therapy; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-6; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2017
Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence. Journal of neuro-oncology, 2017, Volume: 133, Issue:3 Topics: Aminolevulinic Acid; Astrocytes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Fluorescent Dyes; Gefitinib; Gene Expression; Glioblastoma; Heme Oxygenase-1; Humans; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger	2017
Epidermal growth factor receptor and ligand family expression and activity in glioblastoma. Journal of neurochemistry, 2018, Volume: 147, Issue:1 Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Ligands; Transforming Growth Factor alpha	2018
Intratumoral heterogeneity of endogenous tumor cell invasive behavior in human glioblastoma. Scientific reports, 2018, 12-20, Volume: 8, Issue:1 Topics: Brain Neoplasms; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Gefitinib; Glioblastoma; Humans; Neoplasm Invasiveness; Primary Cell Culture; Tissue Culture Techniques; Tumor Cells, Cultured	2018
In silico analysis identified miRNA‑based therapeutic agents against glioblastoma multiforme. Oncology reports, 2019, Volume: 41, Issue:4 Topics: Androstadienes; Antineoplastic Agents; Brain Neoplasms; Computational Biology; Drug Discovery; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glioblastoma; Humans; MicroRNAs; Molecular Docking Simulation; Molecular Targeted Therapy; Sulfonamides; Transcriptome	2019
A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance. CNS neuroscience & therapeutics, 2013, Volume: 19, Issue:7 Topics: AC133 Antigen; Adolescent; Adult; Animals; Antigens, CD; Antineoplastic Agents; Brain Neoplasms; Drug Resistance; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Glioblastoma; Glycoproteins; Humans; Immunohistochemistry; Immunomagnetic Separation; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Transplantation; Peptides; Quinazolines; Real-Time Polymerase Chain Reaction; Stem Cells; Young Adult	2013
Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa. PloS one, 2013, Volume: 8, Issue:5 Topics: Amino Acids; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gefitinib; Glioblastoma; Glutamic Acid; Humans; Quinazolines; Riluzole; Xanthenes	2013
Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma. Neuro-oncology, 2013, Volume: 15, Issue:8 Topics: Cell Movement; Cell Proliferation; Cohort Studies; ErbB Receptors; Gefitinib; Gene Amplification; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Organ Culture Techniques; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured	2013
Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma. Cancer research, 2013, Aug-15, Volume: 73, Issue:16 Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Capillary Permeability; Cell Line, Tumor; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Glioblastoma; Humans; Male; Mice; Mice, Nude; Phosphorylation; Quinazolines; Xenograft Model Antitumor Assays	2013
Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions. Neuro-oncology, 2013, Volume: 15, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cell Line, Tumor; Drug Interactions; Gefitinib; Glioblastoma; Humans; Quinazolines; Sertraline; Stilbenes	2013
Statistical and practical considerations for clinical evaluation of predictive biomarkers. Journal of the National Cancer Institute, 2013, Nov-20, Volume: 105, Issue:22 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins	2013
Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells. Journal of cell science, 2014, Aug-15, Volume: 127, Issue:Pt 16 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Indoles; MAP Kinase Signaling System; Mice, Nude; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-met; Quinazolines; STAT3 Transcription Factor; Sulfones	2014
Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. Oncogene, 2015, Jul-30, Volume: 34, Issue:31 Topics: Animals; Brain Neoplasms; Cell Movement; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mice; Mice, Nude; Phosphorylation; Quinazolines; Receptors, Urokinase Plasminogen Activator; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Tumor Cells, Cultured	2015
Gefitinib inhibits sodium phosphate co-transporter III isoform 1 in a model of human malignant glioma. Anticancer research, 2014, Volume: 34, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Neoplasm Grading; Phosphates; Protein Isoforms; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sodium-Phosphate Cotransporter Proteins, Type III; Tumor Cells, Cultured	2014
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer research, 2015, Jan-15, Volume: 75, Issue:2 Topics: Animals; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glioblastoma; Heterografts; Humans; Membrane Proteins; Mice; Mice, Nude; Proto-Oncogene Proteins; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction	2015
The evidence of glioblastoma heterogeneity. Scientific reports, 2015, Jan-27, Volume: 5 Topics: Animals; Antigens, CD; Brain Neoplasms; Collagen Type I; Collagen Type I, alpha 1 Chain; Disease Models, Animal; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Insulin-Like Growth Factor Binding Proteins; Kaplan-Meier Estimate; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured	2015
ROS1 amplification mediates resistance to gefitinib in glioblastoma cells. Oncotarget, 2015, Aug-21, Volume: 6, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Drug Synergism; Gefitinib; Gene Amplification; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinazolines; S Phase	2015
EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells. Oncotarget, 2015, Oct-20, Volume: 6, Issue:32 Topics: Antineoplastic Agents; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cell Survival; DNA Breaks, Double-Stranded; DNA Repair; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Microscopy, Fluorescence; Quinazolines; Radiation Tolerance; Signal Transduction; X-Rays	2015
Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells. Oncotarget, 2015, Nov-10, Volume: 6, Issue:35 Topics: Antineoplastic Agents; Apoptosis; Aptamers, Nucleotide; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Immunoenzyme Techniques; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Phosphorylation; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured	2015
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Apr-01, Volume: 22, Issue:7 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Insulin; Insulin-Like Growth Factor I; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays	2016
β-Elemene enhances the efficacy of gefitinib on glioblastoma multiforme cells through the inhibition of the EGFR signaling pathway. International journal of oncology, 2016, Volume: 49, Issue:4 Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Quinazolines; Sesquiterpenes; Signal Transduction	2016
Case-specific potentiation of glioblastoma drugs by pterostilbene. Oncotarget, 2016, 11-08, Volume: 7, Issue:45 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Copy Number Variations; Drug Synergism; Female; Gefitinib; Gene Expression Profiling; Gene Knockdown Techniques; Glioblastoma; Humans; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Stilbenes; Transcriptome	2016
Oncogenes Activate an Autonomous Transcriptional Regulatory Circuit That Drives Glioblastoma. Cell reports, 2017, 01-24, Volume: 18, Issue:4 Topics: Animals; Astrocytes; Brain; Brain Neoplasms; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Down-Regulation; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Grading; Oligodendrocyte Transcription Factor 2; Plasmids; Plicamycin; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; RNA Interference; SOXB1 Transcription Factors; Zinc Finger E-box-Binding Homeobox 1	2017
Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells. Journal of neuro-oncology, 2017, Volume: 132, Issue:2 Topics: AC133 Antigen; Animals; Brain Neoplasms; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Embryo, Mammalian; Enzyme Inhibitors; Female; Gefitinib; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Naphthyridines; Neoplastic Stem Cells; Phenazines; Pregnancy; Quinazolines; RNA, Small Interfering; Signal Transduction; Xenograft Model Antitumor Assays	2017
Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells. Scientific reports, 2017, 03-13, Volume: 7 Topics: Anoikis; Antineoplastic Agents; Brain Neoplasms; Cell Adhesion; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Gefitinib; Glioblastoma; Humans; Neovascularization, Pathologic; Phenylurea Compounds; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor	2017
Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. Journal of neuro-oncology, 2008, Volume: 90, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Glioblastoma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; PTEN Phosphohydrolase; Quinazolines	2008
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. Journal of experimental therapeutics & oncology, 2008, Volume: 7, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles	2008
Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Molecular cancer therapeutics, 2009, Volume: 8, Issue:6 Topics: Algorithms; Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Quinazolines; Therapeutic Equivalency; Tumor Burden; Xenograft Model Antitumor Assays	2009
EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. Cancer letters, 2010, Aug-01, Volume: 294, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; DNA Transposable Elements; ErbB Receptors; Female; Gefitinib; Genetic Variation; Glioblastoma; Humans; Mitochondria; Proto-Oncogene Proteins; Quinazolines; Sequence Deletion; Transplantation, Heterologous	2010
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models. Biochemical and biophysical research communications, 2011, Jul-22, Volume: 411, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gefitinib; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Models, Biological; Phenylbutyrates; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Stem Cell Assay	2011
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, Sep-20, Volume: 108, Issue:38 Topics: Animals; Antibiotics, Antineoplastic; Brain; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Immunoblotting; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Receptors, Urokinase Plasminogen Activator; RNA Interference; STAT5 Transcription Factor; Transplantation, Heterologous; Tyrosine	2011
Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation. Cancer research, 2011, Dec-01, Volume: 71, Issue:23 Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Enzyme Activation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Ligands; Membrane Proteins; Mice; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction	2011
Evaluation of antitumor activity of gefitinib in pediatric glioblastoma and neuroblastoma cells. Clinical laboratory, 2011, Volume: 57, Issue:9-10 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gefitinib; Glioblastoma; Humans; Neuroblastoma; Phosphorylation; Quinazolines; Receptor, ErbB-2	2011
Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model. Journal of pharmaceutical sciences, 2012, Volume: 101, Issue:11 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chromatography, Liquid; Gefitinib; Glioblastoma; Mice; Models, Biological; Quinazolines; Tandem Mass Spectrometry	2012
Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. PloS one, 2012, Volume: 7, Issue:10 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Female; Gefitinib; Glioblastoma; Humans; Immunoblotting; Indoles; Inhibitory Concentration 50; Mice; Mice, Nude; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Rats, Inbred F344; Spheroids, Cellular; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays	2012
Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). Cancer letters, 2003, Dec-08, Volume: 202, Issue:1 Topics: Antineoplastic Agents; Brain Neoplasms; Cell Division; Cerebellum; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Phosphorylation; Placenta; Quinazolines; Radiation-Sensitizing Agents; Radiation, Ionizing; Radiotherapy Dosage; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay	2003
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-01, Volume: 10, Issue:9 Topics: Animals; Cell Division; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mice; Mutation; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Swiss 3T3 Cells; Time Factors	2004
Gefitinib in recurrent glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-01, Volume: 22, Issue:13 Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Endpoint Determination; Epidermal Growth Factor; Gefitinib; Glioblastoma; Humans; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results	2004
EGFR mutations and sensitivity to gefitinib. The New England journal of medicine, 2004, Sep-16, Volume: 351, Issue:12 Topics: Antineoplastic Agents; Brain Neoplasms; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines	2004
Somatic mutations of EGFR in colorectal cancers and glioblastomas. The New England journal of medicine, 2004, Dec-30, Volume: 351, Issue:27 Topics: Brain Neoplasms; Colorectal Neoplasms; DNA, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Glioblastoma; Point Mutation; Quinazolines	2004
EGFR tyrosine kinase domain mutations in human gliomas. Neurology, 2005, Apr-26, Volume: 64, Issue:8 Topics: Astrocytoma; Brain Neoplasms; Carcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Testing; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Oligodendroglioma; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines	2005
Glioblastoma multiforme and the epidermal growth factor receptor. The New England journal of medicine, 2005, Nov-10, Volume: 353, Issue:19 Topics: Amino Acid Sequence; Base Sequence; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Gene Expression; Glioblastoma; Humans; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines	2005
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England journal of medicine, 2005, Nov-10, Volume: 353, Issue:19 Topics: Adult; Aged; Antineoplastic Agents; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Gene Deletion; Gene Expression; Genes, erbB-1; Genes, erbB-2; Glioblastoma; Humans; Male; Middle Aged; Mutation; Oligodendroglioma; Polymerase Chain Reaction; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Sequence Analysis, DNA; Signal Transduction	2005
Response of glioblastomas to EGFR kinase inhibitors. The New England journal of medicine, 2006, Feb-02, Volume: 354, Issue:5 Topics: ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Glioblastoma; Humans; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction	2006
Gefitinib accumulation in glioblastoma tissue. Cancer biology & therapy, 2006, Volume: 5, Issue:5 Topics: Antineoplastic Agents; Brain Neoplasms; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mass Spectrometry; Quinazolines	2006
Gefitinib concentrations in human glioblastoma tissue. Journal of neuro-oncology, 2007, Volume: 82, Issue:2 Topics: Antineoplastic Agents; Biological Availability; Brain Neoplasms; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Quinazolines	2007
Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Molecular cancer therapeutics, 2008, Volume: 7, Issue:2 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Male; Mice; Mice, Nude; Models, Biological; Mutation; Pharmacogenetics; Quinazolines; Xenograft Model Antitumor Assays	2008